ArticleBMC infectious diseases2026
Epidemiological characteristics of rotavirus among children aged 5 years and under in Zhangzhou, China, 2023-2024.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesTo investigate the molecular epidemiology of Rotavirus alphagastroenteritidis (RVA) among children with acute gastroenteritis (AGE) in Zhangzhou, China, during 2023-2024.
methodsStool samples were collected from children diagnosed with AGE and were screened for RVA presence using immunochromatography. The partial VP4 and VP7 genes of RVA-positive samples were amplified and sequenced for phylogenetic analysis.
resultsRVA was detected in 10.98% (202/1839) of the samples. Notably, the highest positivity rate was observed in children aged 4-5 years. Among 202 RVA-positive samples, 8 different RVA genotypes were detected with different frequencies. Overall, G8P[8] (62.02%) was the most common RVA genotype, followed by G1P[8] (16.28%), G3P[8] (14.73%) and G9P[8] (13.18%). Phylogenetic analysis of the VP7 gene demonstrated that the G8 strains were clustered within G8-Ⅵ lineage, exhibiting close genetic similarity to contemporary strains circulating in Japan and Southeast Asia. Simultaneously, the VP4 gene of all P[8] strains was classified within the P[8]- Ⅲ lineage, which is distinct from P[8] lineages found in currently licensed RVA vaccines.
conclusionsThis study provides the first documented evidence of the predominance of the G8P[8] genotype in Zhangzhou, suggesting its emergence as the dominant genotype within this population. The findings underscore the dynamic evolutionary patterns of RVA in the region and highlight the urgent necessity for ongoing molecular surveillance. Such efforts are essential to monitor emerging strains, assess potential vaccine mismatches, and guide future immunization strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.